retatrutide phase 3 2025 triple agonist glp-1 gip glucagon A review of an investigational drug retatrutide, a novel agent for the treatment of obesity | European Journal of Clinical Pharmacology Structural insights into the triple

Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia

Purple corn anthocyanin extract improves oxidative stress of rats fed high fat diet via superoxide dismutase mechanism

The trade-off is a higher incidence of gastrointestinal side effects

With better absorption comes the potential for faster recovery and management of the condition

In this review, we discuss the pipeline of obesity pharmacotherapies with focus on entero-pancreatic hormone-based molecules, and we evaluate the data from early and late phase clinical trials on their safety and efficacy on WL in people with and without T2D

Omega-3 fatty acids: 1,000-2,000mg EPA/DHA daily